Government-Owned Inventions; Availability for Licensing, 30543-30544 [2016-11555]
Download as PDF
<![CDATA[
30543
Federal Register / Vol. 81, No. 95 / Tuesday, May 17, 2016 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Total ...................................................................................................
Dated: May 11, 2016.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
[FR Doc. 2016–11618 Filed 5–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Method for
Purifying Antibodies.
Description of Technology: This
technology is a method for purifying a
biologic composition, comprising
jstallworth on DSK7TPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
15:32 May 16, 2016
Jkt 238001
Estimated
number of
responses per
respondent
Average
burden hours
per response
........................
........................
Number of
respondents
Type of respondent
13,218
diafiltering the biologic composition
into a composition comprising
phosphate buffered saline (PBS) to
obtain a purified composition. The
method is particularly useful for
removing one or more impurities from
the biologic composition, such as bis(2hydroxyethyl)aminotris(hydroxymethyl)methane (Bistris).The technology is directed to large
scale manufacturing of Chimeric 14.18
(Ch14.18) monoclonal antibodies.
Ch14.18 is an anti-GD2 monoclonal
antibody and has been described in
Gillies et al., Journal of Immunological
Methods 125:191–202 (1989).
Potential Commercial Applications:
• Large scale manufacturing of
chimeric monoclonal antibodies
Value Proposition:
• Cost effective means of removing
impurities to produce GMP grade
chimeric antibodies for regulatory
approval.
Development Stage: Clinical Phase II,
FDA/EMA approved Chemistry,
Manufacturing and Controls (CMC) large
scale manufacturing to produce GMP
grade chimeric antibodies.
Inventor(s): David A. Meh (United
Therapeutics Corporation), Timothy
Atolagbe (United Therapeutics
Corporation), G. Mark Farquharson
(United Therapeutics Corporation),
Samir Shaban (National Cancer
Institute), Mary Koleck (National Cancer
Institute), George Mitra (National Cancer
Institute).
Intellectual Property:
HHS Ref. No. E–291–2014/0–US–01,
corresponding to US Provisional Patent
App. No. 62/028,994, filed July 25,
2014, entitled ‘‘Method for Purifying
Antibodies using PBS’’
HHS Ref. No. E–291–2014/0–US–02,
corresponding to US Patent App. No.
14/809,211, filed July 25, 2015, entitled
‘‘Method for Purifying Antibodies using
PBS’’
HHS Ref. No. E–291–2014/0–PCT–03,
corresponding to International Patent
App. No. PCT/US2015/042241, filed
July 27, 2015, entitled ‘‘Method for
Purifying Antibodies’’
Publications:
1. FDA published document: https://
www.accessdata.fda.gov/drugsatfda_
docs/nda/2015/
125516Orig1s000TOC.cfm
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
Annual
burden hours
requested
33,242
2. US Food and Drug Administration.
FDA approves first therapy for high-risk
neuroblastoma.https://www.fda.gov/
NewsEvents/Newsroom/
PressAnnouncements/ucm437460.htm
3. WO2016015048 METHOD FOR
PURIFYING ANTIBODIES https://
patentscope.wipo.int/search/en/
detail.jsf?docId=WO2016015048
Contact Information: Requests for
copies of the patent application or
inquiries about licensing, research
collaborations, and co-development
opportunities should be sent to John D.
Hewes, Ph.D., email: john.hewes@
nih.gov.
Dated: May 11, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology
Transfer Center, National Cancer Institute.
[FR Doc. 2016–11556 Filed 5–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below may be
SUMMARY:
E:\FR\FM\17MYN1.SGM
17MYN1
jstallworth on DSK7TPTVN1PROD with NOTICES
30544
Federal Register / Vol. 81, No. 95 / Tuesday, May 17, 2016 / Notices
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Improved Pepper
Spray for Repellency and
Incapacitation.
Description of Technology: Non-lethal
means of temporarily incapacitating a
person are greatly needed for law
enforcement and for personal
protection. A common approach is to
use pepper spray. Although current
pepper sprays are effective, they cause
pain for excessively long periods, and
could be life threatening for people who
suffer from asthma and have
hypersensitive airways. This technology
describes a composition for use in an
aerosol or spray, that when
administered, causes a painful
stimulation and incapacitates a person
for only a brief period. This technology
may improve safety over currently
available pepper sprays.
Potential Commercial Applications:
• Law enforcement (policing, riot
control, crowd control)
• Incapacitating agent for use in
hostage situations
• Personal self-defense
Value Proposition:
• Incapacitating pepper spray with
reduced toxicity and enhanced safety.
• May reduce potential agency
liability in case of an adverse response
of an individual who was sprayed (due
to reduced toxicity may not be as life
threatening to those suffering from
asthma or have hypersensitive airways
as standard pepper sprays).
• Mixture can be incorporated into a
spray, aerosol, or other dispersions.
Development Stage: Basic (Target ID).
Inventor(s): Peter M. Blumberg (NCI),
Larry V. Pearce (NCI).
Intellectual Property:
HHS Reference No. E–048–2010/0.
U.S. Provisional Application 61/
340,063 (HHS Reference No. E–048–
2010/0–US–01) filed March 12, 2010
entitled, ‘‘Improved Pepper Spray for
Repellency and Incapacitation of People
and Animals’’.
PCT Application PCT/US2011/028132
(HHS Reference No. E–048–2010/0–
PCT–02) filed March 11, 2011 entitled,
‘‘Agonist/Antagonist Compositions and
Methods of Use’’.
Canada: Application 2,792, 878 (HHS
Reference No. E–048–2010/0–CA–03)
VerDate Sep<11>2014
15:32 May 16, 2016
Jkt 238001
filed March 11, 2011 entitled, ‘‘Agonist/
Antagonist Compositions and Methods
of Use’’ (Pending).
U.S. Patent Application 13/634,447
(HHS Reference No. E–048–2010/0–US–
04) filed September 12, 2012 entitled,
‘‘Agonist/Antagonist Compositions and
Methods of Use’’.
U.S. Patent Application 15/010,830
(HHS Reference No. E–048–2010/0–US–
05) filed January 29, 2016 entitled,
‘‘Agonist/Antagonist Compositions and
Methods of Use’’ (Pending).
Collaboration Opportunity:
Researchers at the NCI seek licensing for
use as a non-lethal incapacitation agent.
Contact Information: Requests for
copies of the patent application or
inquiries about licensing, research
collaborations, and co-development
opportunities should be sent to John D.
Hewes, Ph.D., email: john.hewes@
nih.gov.
Dated: May 11, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology
Transfer Center, National Cancer Institute.
[FR Doc. 2016–11555 Filed 5–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Investigator Initiated
Extended Clinical Trial (R01).
Date: June 6, 2016.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health 3C100,
5601 Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Yong Gao, Ph.D., Scientific
Review Officer Scientific Review Program,
PO 00000
Frm 00030
Fmt 4703
Sfmt 9990
Division of Extramural Activities, Room
#3G13B, National Institutes of Health/NIAID,
5601 Fishers Lane, MSC 9823, Rockville, MD
20892–7616, (240) 669–5048, yong.gao@
nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Investigator Initiated
Extended Clinical Trial (R01).
Date: June 6, 2016.
Time: 2:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 3C100,
5601 Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Yong Gao, Ph.D., Scientific
Review Officer, Scientific Review Program,
Division of Extramural Activities, Room
#3G13B, National Institutes of Health/NIAID,
5601 Fishers Lane, MSC 9823, Rockville, MD
20892–7616, (240) 669–5048, .gao@nih.gov.
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Microbiology and Infectious Diseases
Research Committee.
Date: June 9–10, 2016.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3F100, 5601 Fishers Lane, Rockville, MD
20892 (Telephone Conference Call).
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer Scientific Review
Program, Division of Extramural Activities,
Room #3E72A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9834,
Bethesda, MD 20892934, (240) 669–5023,
fdesilva@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Rapid Assessment of Zika
Virus (ZIKV) Complications (R21).
Date: June 13, 2016.
Time: 9:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3C100, 5601 Fishers Lane, Rockville, MD
20892 (Telephone Conference Call).
Contact Person: Uday K. Shankar, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room #3G21B, National Institutes of Health,
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, (240) 669–5051,
uday.shankar@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 11, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–11553 Filed 5–16–16; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\17MYN1.SGM
17MYN1
]]>Agencies
[Federal Register Volume 81, Number 95 (Tuesday, May 17, 2016)]
[Notices]
[Pages 30543-30544]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-11555]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve
expeditious commercialization of results of federally-funded research
and development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing and/or co-development.
ADDRESSES: Invention Development and Marketing Unit, Technology
Transfer Center, National Cancer Institute, 9609 Medical Center Drive,
Mail Stop 9702, Rockville, MD 20850-9702.
FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent
applications listed below may be
[[Page 30544]]
obtained by contacting: Attn. Invention Development and Marketing Unit,
Technology Transfer Center, National Cancer Institute, 9609 Medical
Center Drive, Mail Stop 9702, Rockville, MD 20850-9702, Tel. 240-276-
5515 or email ncitechtransfer@mail.nih.gov. A signed Confidential
Disclosure Agreement may be required to receive copies of the patent
applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Title of invention: Improved Pepper Spray for Repellency and
Incapacitation.
Description of Technology: Non-lethal means of temporarily
incapacitating a person are greatly needed for law enforcement and for
personal protection. A common approach is to use pepper spray. Although
current pepper sprays are effective, they cause pain for excessively
long periods, and could be life threatening for people who suffer from
asthma and have hypersensitive airways. This technology describes a
composition for use in an aerosol or spray, that when administered,
causes a painful stimulation and incapacitates a person for only a
brief period. This technology may improve safety over currently
available pepper sprays.
Potential Commercial Applications:
Law enforcement (policing, riot control, crowd control)
Incapacitating agent for use in hostage situations
Personal self-defense
Value Proposition:
Incapacitating pepper spray with reduced toxicity and
enhanced safety.
May reduce potential agency liability in case of an
adverse response of an individual who was sprayed (due to reduced
toxicity may not be as life threatening to those suffering from asthma
or have hypersensitive airways as standard pepper sprays).
Mixture can be incorporated into a spray, aerosol, or
other dispersions.
Development Stage: Basic (Target ID).
Inventor(s): Peter M. Blumberg (NCI), Larry V. Pearce (NCI).
Intellectual Property:
HHS Reference No. E-048-2010/0.
U.S. Provisional Application 61/340,063 (HHS Reference No. E-048-
2010/0-US-01) filed March 12, 2010 entitled, ``Improved Pepper Spray
for Repellency and Incapacitation of People and Animals''.
PCT Application PCT/US2011/028132 (HHS Reference No. E-048-2010/0-
PCT-02) filed March 11, 2011 entitled, ``Agonist/Antagonist
Compositions and Methods of Use''.
Canada: Application 2,792, 878 (HHS Reference No. E-048-2010/0-CA-
03) filed March 11, 2011 entitled, ``Agonist/Antagonist Compositions
and Methods of Use'' (Pending).
U.S. Patent Application 13/634,447 (HHS Reference No. E-048-2010/0-
US-04) filed September 12, 2012 entitled, ``Agonist/Antagonist
Compositions and Methods of Use''.
U.S. Patent Application 15/010,830 (HHS Reference No. E-048-2010/0-
US-05) filed January 29, 2016 entitled, ``Agonist/Antagonist
Compositions and Methods of Use'' (Pending).
Collaboration Opportunity: Researchers at the NCI seek licensing
for use as a non-lethal incapacitation agent.
Contact Information: Requests for copies of the patent application
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D.,
email: john.hewes@nih.gov.
Dated: May 11, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National
Cancer Institute.
[FR Doc. 2016-11555 Filed 5-16-16; 8:45 am]
BILLING CODE 4140-01-P
